May 19, 2017

One in five cancers diagnosed in U.S. is rare

Richard Drew / AP

A new study found 1 in 5 cancers diagnosed in the U.S. is a rare cancer. The details:

  • For people 20 years or younger, two out of three cancers diagnosed are rare.
  • More Hispanic (24%) and Asian/Pacific Islander (22%) patients are diagnosed with rare cancers compared with non-Hispanic blacks (20%) and non-Hispanic whites (19%).
  • The five-year survival rate for rare cancers is poorer than that for common cancers in both males (55% vs. 75%) and females (60% vs. 74%) due to delays in diagnosis and fewer treatment options.

The definition: In the study, a "rare cancer" is defined as one diagnosed with fewer than six cases per 100,000 individuals per year. (There is no universally adopted definition of rare cancer; for instance, the National Cancer Institute defines rare cancers as fewer than 15 cases per 100,000 people per year.) The study examined incidence rates, stage at diagnosis, and survival rates for 181 rare cancers.

Some good news: The five-year relative survival rate is substantially higher (82%) for people younger than 20 diagnosed with a rare cancer than for adults aged 65-79 years (46%). But that's just one measure of cancer patients' health — childhood cancer survivors in particular can experience life-long health effects.

What's next: The proportion of rare cancers is likely to grow because molecular techniques are finding more differences and therefore more classifications of cancers. "Continued efforts are needed to develop interventions for prevention, early detection, and treatment to reduce the burden of rare cancers. Such discoveries can often advance knowledge for all cancers."

Go deeper

Exclusive: Global trust in the tech industry is slipping

Illustration: Aïda Amer/Axios

The backlash against Big Tech has long flourished among pundits and policymakers, but a new survey suggests it's beginning to show up in popular opinion as well.

Driving the news: New data from Edelman out Tuesday finds that trust in tech companies is declining and that people trust cutting-edge technologies like artificial intelligence less than they do the industry overall.

"It was 30 years ago, get over it": Mike Bloomberg's partner brushes off NDA concerns

Diana Taylor at a Mike Bloomberg event last month. Photo: Ron Adar/Echoes Wire/Barcroft Media via Getty Images

Diana Taylor, Mike Bloomberg's longtime partner, dismissed the concerns surrounding non-disclosure agreements used at his company, Bloomberg LP, telling CBS News that she would say to those bothered by the allegations, "It was 30 years ago, get over it."

Why it matters: Democratic candidates have used the NDAs as a talking point against Bloomberg, calling on him to allow women to speak about the reported sexual harassment and gender discrimination they faced while working for him.

Trump's opportunity to use Bernie as an economic scapegoat

Illustration: Aïda Amer/Axios. Photos: Zach Gibson/Stringer, The Washington Post/Getty Contributor

Bernie Sanders is poised to become an economic scapegoat for both the White House and Corporate America, assuming that Sanders comes through Super Tuesday unscathed.

The big picture: If the U.S. economy remains strong, President Trump and CEOs will claim credit (as they've been doing for three years). If it turns sour, they'll blame Bernie (even though it's a largely baseless charge).